Skip to main content
Fig. 5 | Molecular Neurodegeneration

Fig. 5

From: Small molecule inhibitors of α-synuclein oligomers identified by targeting early dopamine-mediated motor impairment in C. elegans

Fig. 5

Acetaminophen, caffeine, losartan, mercaptopurine, rapamycin, and rifabutin reduce α-synuclein oligomers in vitro. (a) Testing of 40 highly ranked compounds (1 μM or 10 μM) for their ability to reduce α-synuclein oligomer levels in vitro using a Gaussia luciferase protein-fragment complementation cell assay. Rapamycin (2 μM) and bafilomycin A1 (50 nM) were used as active controls (N = 4 for each treatment) (one-tailed t-test, *p < 0.05). (b) Etoposide, piroxicam, theophylline, and vincristine demonstrated reductions in viability at multiple concentrations, measured using PrestoBlue-mediated fluorescence and normalized to vehicle alone (N = 3 with n = 2–4 replicates for each concentration) (one-way ANOVA with Dunnett’s post-hoc test, *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001). No statistically significant changes in viability were observed with acetaminophen, caffeine, losartan, mercaptopurine, rapamycin, or rifabutin. (c) No statistically significant changes in the activity of full-length Gaussia luciferase alone were found with acetaminophen, caffeine, losartan, mercaptopurine, rapamycin, or rifabutin (N = 2 with n = 8 replicates for each concentration) (one-way ANOVA with Dunnett’s post-hoc test)

Back to article page